Table 2.
The immediate risk of CIN2+ lesion according to HPV status in LSIL patients (n=318)
| HPV status | N | Immediate risk of CIN2+ lesion (% [95%CI]) |
|---|---|---|
| Regardless of HPV status | 318 | 6 (3.6–9.2) |
| HPV HR− | 130 | 3.1 (0.8–7.7) |
| HPV HR+ | 188 | 8 (4.5–12.8) |
| HPV16+ | 29 | 20.7 (8–39.7) |
| HPV18+ | 15 | 13.3 (1.7–10.5) |
| HPV 16/18+ | 42 | 16.7 (7–31.4) |
| HPV HR non-16/18+ | 146 | 5.5 (2.4–10.5) |
| HPV68+ | 9 | 11.2 (0.3–48.2) |
| HPV33+ | 10 | 10 (0.3–44.5) |
| HPV52+ | 25 | 8 (1–26) |
| HPV56+ | 26 | 7.7 (0.9–25.1) |
| HPV39+ | 14 | 7 (2–33.9) |
| HPV58+ | 30 | 6.7 (0.8–22.1) |
| HPV51+ | 31 | 6.5 (0.8–21.4) |
| HPV66+ | 59 | 5.1 (1.1–14.1) |
| HPV31+ | 8 | 0 (0–36.9) |
| HPV35+ | 2 | 0 (0–84.2) |
| HPV45+ | 3 | 0 (0–70.8) |
| HPV59+ | 12 | 0 (0–26.5) |
CIN2+, cervical intraepithelial neoplasia 2 or higher lesion; HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; CI, confidence interval; HR, high risk; −, negative; +, positive.